Bríd M Ryan

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint The hallmarks of premalignant conditions: a molecular basis for cancer prevention
    Bríd M Ryan
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA Electronic address
    Semin Oncol 43:22-35. 2016
  2. pmc Asymmetric segregation of template DNA strands in basal-like human breast cancer cell lines
    Wenyu Liu
    Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey, USA
    Mol Cancer 12:139. 2013
  3. doi request reprint Survivin: a new target for anti-cancer therapy
    Bríd M Ryan
    Cancer Prevention Fellowship Program, Office of Preventive Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4258, USA
    Cancer Treat Rev 35:553-62. 2009

Collaborators

Detail Information

Publications3

  1. doi request reprint The hallmarks of premalignant conditions: a molecular basis for cancer prevention
    Bríd M Ryan
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA Electronic address
    Semin Oncol 43:22-35. 2016
    ..These differences must be kept in mind, and indeed leveraged, when exploring potential cancer prevention measures. ..
  2. pmc Asymmetric segregation of template DNA strands in basal-like human breast cancer cell lines
    Wenyu Liu
    Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey, USA
    Mol Cancer 12:139. 2013
    ..We tested if co-culture with human mesenchymal stem cells, which are known to increase self-renewal, can alter the frequency of asymmetric segregation of template DNA in breast cancer...
  3. doi request reprint Survivin: a new target for anti-cancer therapy
    Bríd M Ryan
    Cancer Prevention Fellowship Program, Office of Preventive Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4258, USA
    Cancer Treat Rev 35:553-62. 2009
    ..The optimum use of survivin antagonists in the treatment of cancer is likely to be in combination with conventional cancer therapies...